Company Overview and News
New Zealand shares fell today as Comvita continued its plunge after an end to takeover talks, and A2 Milk took losses.
New Zealand shares dropped, led lower by Comvita as its possible takeover failed, with A2 Milk continuing last week's losses and Kiwi Property Group dropping on its earnings.
New Zealand shares rose, led by A2 Milk Co and Synlait Milk while Pushpay fell after annual earnings met its guidance, disappointing some upbeat investors.
New Zealand shares fell as A2 Milk Co disappointed investors with a market update, dragging down partner Synlait Milk.
An MSCI index reshuffle sent shares for Fletcher Building soaring after it survived, but Mercury Energy shares fell as it was culled from the index.
New Zealand shares dipped from a record high, with Air New Zealand and Mercury New Zealand falling while Synlait Milk and Fletcher Building gained.
A review of global stock indices by MSCI will, as expected, add A2 Milk to the international investment advisor's main global index, with Mercury New Zealand to be removed.
A review of global stock indices by MSCI has seen Fletcher Building shares gain after news the stock will remain on the international investment adviser's main global index, with A2 Milk rising on its planned entry and Mercury New Zealand dipping due to its planned removal.
New Zealand shares rose ahead of the MSCI rebalancing tomorrow, with possible addition A2 Milk leading gains while Fletcher Building and Mercury New Zealand, rumoured to be leaving, dropped.
New Zealand's benchmark stock index rose to a fresh record, led by retirement village operator Ryman Healthcare and Fisher & Paykel Healthcare Corp, while Pushpay fell.
New Zealand shares were mixed, with A2 Milk pulling the index up while Gentrack Group, Spark New Zealand and banking stocks dropped.
New Zealand shares gained, led by Z Energy following its annual results, with Chorus and Genesis also rising.
Fonterra Cooperative Group's milk collection this season is tracking 2 per cent lower than in 2017, a steeper decline than for the industry as a whole and suggesting rivals have picked up more of the national milk pool.
New Zealand shares rallied across the board, with Mercury New Zealand and Kiwi Property Group leading the index while Scales Corp and Comvita dropped.
One of the major challenges facing investors is that fast-growing US companies have a strong focus on intangible assets, instead of the more traditional physical assets.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...